ICICI Prudential Nifty Pharma Index Fund

A Index Funds scheme from ICICI Prudential Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF109KC11M9).

NAV ₹21.7502 on 16 November 2026.

Expense ratio

Total expense ratio 0.51% a year for the Direct · Growth plan, as AMFI published it on 28 October 2026: base expense ratio 0.32%, brokerage 0.01%, transaction costs 0.00%, statutory levies including GST 0.18%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year25.3%14.8%-7.5%1.241.40
3 years22.6%15.3%-16.6%1.021.03

Too little NAV history for the 5, 10-year figures.

Not ranked in its category: its category mixes funds too different to rank against one another.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 99.9% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 18.60%
  2. Divi's Laboratories Limited — 12.28%
  3. Laurus Labs Limited — 9.26%
  4. Dr. Reddy's Laboratories Limited — 8.15%
  5. Cipla Limited — 7.67%
  6. Torrent Pharmaceuticals Limited — 6.71%
  7. Lupin Limited — 4.83%
  8. Aurobindo Pharma Limited — 4.59%
  9. Glenmark Pharmaceuticals Limited — 3.42%
  10. Zydus Lifesciences Limited — 3.05%

Plans

Other funds in Index Funds

All 275 funds in Index Funds · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.